Opinion|Videos|September 9, 2024
Oral JAK inhibitors and Their Use for Treatment of Atopic Dermatitis
Medical experts review the FDA-approved oral JAK inhibitors for atopic dermatitis (abrocitinib, upadacitinib), highlighting differences from conventional therapies, their appeal, and the criteria for recommending them based on disease severity and patient characteristics.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please review oral JAK inhibitors that are FDA approved for atopic dermatitis (AD) (abrocitinib, upadacitinib).
- Are there any differences in the mechanism of action of FDA-approved JAK inhibitors compared with conventional therapies that are important for prescribers to know?
- Why is treatment with oral JAK inhibitors an attractive option for AD?
- At what point during a patient’s treatment journey would you recommend use of JAK inhibitors?
- How does disease severity affect your recommendation?
- In which patients would you consider using a JAK inhibitor? Please describe characteristics of an ideal patient for oral JAK inhibitor.
Advertisement
Related to this article
KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, examine how ORAL Surveillance shaped JAK warnings and what long-term atopic dermatitis data show.
In a phase 2 decentralized study, once-daily trientine tetrahydrochloride improved convenience and adherence in Wilson disease; 80% preferred it.
Type 2 biologics reduced mucus plugs in asthma trials, and quantitative imaging may help detect this treatable phenotype, according to a GOLD 2026 session.
In adults with late-onset PFIC, odevixibat improved pruritus within 3 months in a real-world study at presented at The Liver Meeting 2026.
CT-detected mucus plugs affect up to 67% of patients with COPD and are linked to worse lung function, exacerbations, and mortality, even without symptoms.
In patients with compensated MASH cirrhosis, Baveno VII and ANTICIPATE-NASH showed moderate agreement with HVPG and underestimated CSPH prevalence.
Advertisement
Advertisement
Trending on HCPLive
1
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
2
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
3
ELSPIRE: Elafibranor Achieves ALP Normalization in 85% With PBC
4
Moving the Needle in Medicine: Mentorship, Teams, and Heart Failure Leadership, With Robert Mentz, MD
5